Same-Day Treatment With Genvoya vs. EFV/TDF/3TC

NCT03405194 · clinicaltrials.gov ↗
NA
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Haiti gained access to dolutegravir as first-line ART, so we cancelled the study before any patient was enrolled (we didn't want SOC group to receive EFV)

Conditions

Interventions

Sponsor

Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic

Collaborators